BBHVanEck Biotech ETF
Fund Description
VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS®US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
-
Fund Ticker
BBH -
Exchange
NASDAQ -
Inception Date
12/20/2011 -
ETF Structure
Physical -
Administrator
Van Eck Associates -
Index Ticker
MVBBHTR -
Index Rebalancing
Quarterly
as of 07/01/22
-
30-Day SEC Yield
0.52% -
Total Net Assets
$458.1M -
Number of Holdings
25 -
Options
Available -
Gross Expense Ratio2
0.35% -
Net Expense Ratio/TER2
0.35% -
Distribution Frequency
Annual -
Next Distribution Date
12/16/2022
Key Points
- Highly Liquid Companies
Index seeks to track the most liquid companies in the industry based on market cap and trading volume
- Industry Leaders
Index methodology favors the largest companies in the industry
- Global Scope
Portfolio may include both domestic and U.S. listed foreign companies allowing for enhanced industry representation
Trading Information
-
Fund Ticker
BBH -
Index Total Return Ticker
MVBBHTR -
NAV
BBHNV -
Intraday NAV (IIV)4
BBHIV -
Shares Outstanding
3,071,503 -
Estimated Cash
BBHEU -
Total Cash
BBHTC -
CUSIP
92189F726 -
ISIN
US92189F7261
Fees and Expenses2
-
Management Fee
0.35% -
Other Expenses
-- -
Acquired Fund Fees and Expenses
-- -
Gross Expense Ratio
0.35% -
Fee Waivers and
--
Expense Reimbursement -
Net Expense Ratio/TER2
0.35%
2'Van Eck Associates Corporation (the “Adviser”) will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses. Notwithstanding the foregoing, the Adviser has agreed to pay the offering costs until at least February 1, 2023.'
Investment Professionals
Peter Liao, CFA
- Portfolio Manager and Head of Equity ETFs
- Oversees the Equity ETF Investment Management Team including development and management of index replication and optimization strategies
- Joined VanEck in 2005
- CFA charterholder; member of the CFA Society New York
- BA, Mathematics and Economics, New York University
Guo Hua (Jason) Jin
- Portfolio Manager and Analyst for Equity ETFs
- Joined VanEck in 2007
- Prior to his current role, held a portfolio administration position at VanEck
- Previously, Portfolio Analyst at Evaluation Associates
- BS, Business Administration (concentration in Financial Analysis), State University of New York at Buffalo
Griffin Driscoll
- Analyst for Equity ETFs
- Joined VanEck in 2018
- Prior to joining VanEck, ETF Basket Operations Analyst at JPMorgan
- BS, Finance, Providence College
Ralph Lasta
- Analyst for Equity ETFs
- Joined VanEck in 2019
- Prior to VanEck, Intermediate Representative, Exchange Traded Funds at BNY Mellon.
- BS, Accounting, Hunter College
Performance History: Average Annual Total Returns* (%)
1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR |
LIFE 12/20/11 |
|
---|---|---|---|---|---|---|---|---|
BBH (NAV) | 1.08 | -5.83 | -21.76 | -19.35 | 8.67 | 5.18 | 12.89 | 15.03 |
BBH (Share Price) | 1.10 | -5.77 | -21.84 | -19.47 | 8.63 | 5.16 | 12.88 | 15.04 |
MVBBHTR (Index) | 1.08 | -5.80 | -21.75 | -19.24 | 8.81 | 5.36 | 13.07 | 15.22 |
Performance Differential (NAV - Index) | -- | -0.03 | -0.01 | -0.11 | -0.14 | -0.18 | -0.18 | -0.19 |
1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR |
LIFE 12/20/11 |
|
---|---|---|---|---|---|---|---|---|
BBH (NAV) | 3.21 | -14.25 | -14.25 | -7.17 | 8.43 | 6.79 | 14.17 | 16.33 |
BBH (Share Price) | 3.23 | -14.37 | -14.37 | -7.39 | 8.39 | 6.79 | 14.13 | 16.33 |
MVBBHTR (Index) | 3.23 | -14.25 | -14.25 | -7.02 | 8.58 | 6.97 | 14.34 | 16.52 |
Performance Differential (NAV - Index) | -0.02 | -- | -- | -0.15 | -0.15 | -0.18 | -0.17 | -0.19 |
Top 10 Holdings (%) as of 05/31/22 Daily Holdings
to view
full data
Holding Name |
Ticker
|
Shares
|
Market Value (US$) |
% of Net Assets |
---|---|---|---|---|
Amgen Inc |
AMGN US |
262,022 |
67,271,528 | 15.16 |
Gilead Sciences Inc |
GILD US |
541,339 |
35,105,834 | 7.91 |
Vertex Pharmaceuticals Inc |
VRTX US |
126,312 |
33,933,719 | 7.65 |
Moderna Inc |
MRNA US |
215,468 |
31,313,964 | 7.06 |
Regeneron Pharmaceuticals Inc |
REGN US |
46,072 |
30,625,901 | 6.90 |
Iqvia Holdings Inc |
IQV US |
104,356 |
22,462,629 | 5.06 |
Biontech Se |
BNTX US |
135,908 |
22,201,931 | 5.00 |
Biogen Inc |
BIIB US |
101,786 |
20,357,200 | 4.59 |
Seagen Inc |
SGEN US |
134,349 |
18,228,472 | 4.11 |
Bio-Techne Corp |
TECH US |
47,713 |
17,640,927 | 3.98 |
Top 10 Total (%) | 67.41 |
Country Weightings (%) as of 05/31/22
-
Country
% of Net Assets -
■
United States
87.61 -
■
Germany
5.00 -
■
Ireland
3.27 -
■
China
2.92 -
■
Switzerland
1.21 -
■
Other/Cash
-0.01
Sector Weightings (%) as of 05/31/22
-
Sector
% of Net Assets -
■
Health Care
100.0 -
■
Other/Cash
0.0